Bioengineering nonprofit Cultivarium is embarking on a three-year journey to develop tools and resources for scientists ...

A new biotech is hitting the Boston scene with $50 million from Flagship Pioneering and a goal of preventing patients from ...

Big Pharma M&A will likely take a hit if the U.S. government lives up to its threats of imposing tariffs on the industry, ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

The Department of Health and Human Services (HHS) is cutting off funding to the long-running Women’s Health Initiative (WHI) ...

Bayer is boosting its precision oncology efforts with a molecular database from health tech firm ConcertAI.  | Bayer is ...

Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ...

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical ...

Boehringer Ingelheim has slipped another piece of its oncology R&D strategy into place, partnering with Tessellate Bio on a ...

Roche’s Genentech has inked a deal with Repertoire Immune Medicines aimed at discovering and developing T-cell-targeted ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...